| Abstract: |
The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject. |
| Inventor: |
Bonn-Miller, Marcel (Lexington, NC, US); Tich, Nancy (Chester, NJ, US); Gutterman, Donna (Raleigh, NC, US); Messenheimer, John (Moncure, NC, US); Sebree, Terri (Gladwyne, PA, US) |
| Applicant: |
ZYNERBA PHARMACEUTICALS, INC. (Devon, PA, US) |
| Face Assignee: |
ZYNERBA PHARMACEUTICALS, INC. (Devon, PA, US) |
| Filed: |
2019-10-07 |
| Issued: |
2020-09-01 |
| Claims: |
7 |
|
US10758497
|
1. A method of treating a human suffering from Fragile X Syndrome comprising: administering 250 mg or 500 mg of synthetic or purified cannabidiol in a pharmaceutically acceptable carrier to the human suffering from Fragile X Syndrome to effectively treat the Fragile X Syndrome in the human in need thereof.
(5)
(0)
|
|
